← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...
HomeStocksMLYSRevenue History
OverviewPriceRevenueEarningsP/ERatiosDividendTargets

Mineralys Therapeutics, Inc. (MLYS) Revenue History

Annual and quarterly revenue from 2020 to 2024

TTM Revenue
$0
0
YoY Growth
-
Latest Quarter
$0
Q3 2025
QoQ Growth
-

Compound Annual Growth Rate (CAGR)

3-Year-
5-Year-
10-Year-
Highest Annual Revenue$0 (0)
Highest Quarter$0 ()

Loading revenue history...

Revenue Growth Metrics

1-Year Growth
-
3-Year CAGR
-
5-Year CAGR
-
10-Year CAGR
-
TTM vs Prior Year-
Peak Annual Revenue$0 (0)

Download Historical Data

5 records • Includes OHLCV + Technical Indicators (MA50, MA200, RSI)

Free sign in required to download data

MLYS Revenue Analysis (2020–2024)

As of March 1, 2026, Mineralys Therapeutics, Inc. (MLYS) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q3 2025) recorded $0 in revenue.

Looking at the longer-term picture, MLYS's historical revenue data shows various trends over time.

When compared to Healthcare sector peers including UTHR (+10.6% YoY), ZLAB (+15.3% YoY), and AMRN (-6.2% YoY). Compare MLYS vs UTHR →

Peer Comparison

Compare MLYS's revenue metrics with industry peers

CompanyTTM RevenueYoY Growth5Y CAGROp. MarginCompare
MLYSCurrent$0---
UTHR$3.2B+10.6%+16.5%46.9%
ZLAB$460M+15.3%+56.5%-49.9%
AMRN$229M-6.2%-11.9%-40.2%
ALKS$1.5B-5.2%+7.3%17.2%
ADMA$426M+27.6%+70.8%32.6%
Best in groupLowest in group

Historical Revenue Data

Showing 5 of 5 records
Year Revenue YoY % Gross Profit Gross Margin Op. Income Op. Margin
2024$0-$0-$-192,403,000-
2023$0-$0-$-84,657,000-
2022$0-$0-$-31,479,000-
2021$0-$0-$-18,725,000-
2020$0-$0-$-2,943,000-

See MLYS's True Return

Price is only half the story. See total return with reinvested dividends.

Launch Calculator

Is MLYS Undervalued?

See our Bear / Base / Bull DCF models and intrinsic value estimates.

View Valuation

Compare MLYS vs AGIO

See how MLYS stacks up against sector leader Agios Pharmaceuticals, Inc..

Start Comparison

Frequently Asked Questions

Is MLYS's revenue growth accelerating or slowing?

MLYS TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.

What is MLYS's long-term revenue growth rate?

Mineralys Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.

How is MLYS's revenue distributed by segment?

MLYS reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2020-2024 are available for download. Segment mix reveals concentration and diversification trends.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.

Revenue Over Time